Therefore, these five anti-PD-1/PD-L1 ICIs have been approved by the U.S. Food and Drug Administration (FDA), for use as a first-line therapy for advanced NSCLC [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.